{
    "nct_id": "NCT06333951",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2024-03-27",
    "study_start_date": "2024-09-17",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Pemetrexed"
            },
            {
                "drug_name": "Drug: Carboplatin"
            },
            {
                "drug_name": "Drug: Paclitaxel"
            },
            {
                "drug_name": "Drug: Sotorasib"
            },
            {
                "drug_name": "Drug: AMG 193"
            },
            {
                "drug_name": "Drug: Pembrolizumab"
            }
        ]
    },
    "long_title": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",
    "last_updated": "2025-08-22",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Amgen",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 500,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria",
        "Subprotocol A, B, and C",
        "* Age \u2265 18 years (or \u2265 legal age within the country if it is older than 18 years).",
        "* Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.",
        "* Homozygous MTAP-deletion",
        "* Able to swallow and retain PO administered study treatment.",
        "* Disease measurable as defined by RECIST v1.1.",
        "Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.",
        "Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):",
        "\\- Predominantly squamous histology.",
        "Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):",
        "\\- Predominantly non-squamous histology.",
        "Arm C (AMG 193 + pembrolizumab):",
        "\\- PD-L1 positive.",
        "Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.",
        "Subprotocol C",
        "* Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.",
        "* Brain lesion meeting RANO-BM criteria for measurable disease.",
        "Exclude - Exclusion Criteria",
        "Exclude - Subprotocol A, B, and C",
        "Exclude - * Cardiovascular and pulmonary exclusion criteria as defined in the protocol.",
        "Exclude - * Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).",
        "Exclude - * History of solid organ transplant.",
        "Exclude - * Major surgery within 28 days of first dose of AMG 193.",
        "Exclude - * Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.",
        "Exclude - * Radiation therapy within 28 days of first dose.",
        "Exclude - Subprotocol A",
        "Exclude - \\- Autoimmune disease or immunodeficiency disease as defined in the protocol'"
    ],
    "short_title": "AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Amgen",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Subprotocol A: Non-Small Cell Lung Cancer (NSCLC) Arm A",
                        "arm_internal_id": 0,
                        "arm_description": "Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 orally (PO) and carboplatin, paclitaxel, and pembrolizumab intravenously (IV)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AMG 193",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Carboplatin",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Paclitaxel",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Subprotocol A: NSCLC Arm B",
                        "arm_internal_id": 1,
                        "arm_description": "Participants with MTAP-deleted NSCLC will receive a regimen of AMG 193 PO and carboplatin, pemetrexed, and pembrolizumab IV",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AMG 193",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Carboplatin",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Pemetrexed",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Subprotocol A: NSCLC Arm C",
                        "arm_internal_id": 2,
                        "arm_description": "Participants with MTAP-deleted NSCLC will receive a combination of AMG 193 PO and pembrolizumab IV",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AMG 193",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Subprotocol B: NSCLC With KRasG12C Mutation",
                        "arm_internal_id": 3,
                        "arm_description": "Participants with MTAP-deleted NSCLC and KRasG12C mutation will receive a combination of AMG 193 and sotorasib PO",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AMG 193",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Sotorasib",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Subprotocol C: NSCLC With Brain Metastases",
                        "arm_internal_id": 4,
                        "arm_description": "Participants with MTAP-deleted NSCLC with brain metastases will receive AMG 193 PO",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AMG 193",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Inflammatory Myofibroblastic Lung Tumor"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Combined Small Cell Lung Carcinoma"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Lung Neuroendocrine Tumor"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Non-Small Cell Lung Cancer"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Pleuropulmonary Blastoma"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Lung Adenocarcinoma In Situ"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Sarcomatoid Carcinoma of the Lung"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Pulmonary Lymphangiomyomatosis"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "clinical": {
                                            "age_numerical": ">=18",
                                            "pdl1_status": "High",
                                            "disease_status": [
                                                "Metastatic"
                                            ]
                                        }
                                    }
                                ]
                            },
                            {
                                "or": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "KRAS",
                                            "variant_category": "Mutation"
                                        }
                                    },
                                    {
                                        "genomic": {
                                            "hugo_symbol": "MTAP",
                                            "variant_category": "Copy Number Variation"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}